Epitalon + DSIP
Hundreds of papers. One laboratory.
Epitalon has been studied for forty years, almost all of it inside one institute in St Petersburg, with no registered human trials and no study of what it does inside a body. DSIP has been named after an effect on sleep since 1977, and nobody has found the receptor it is supposed to act on. Both halves are sold on a mechanism nobody has located.
Both go in before bed, and that is most of the argument.
People reach for this pairing for sleep. Epitalon came out of the pineal gland, the part of the brain that sets sleep timing, and DSIP is named after the slow brain waves of deep sleep. Both are taken at night. The anti-ageing claims are the longer-term draw and the sleep is the near-term one, which is why the two get combined at all.
We have no measured data on what either compound does to sleep in the people buying them. Nobody has run that study, and reported experience online is not something we can verify or count.
Epitalon is run in short courses of a week or two instead of continuously, which is unusual and is the main practical thing to know about it.
People combine them because the timing lines up and because both are aimed loosely at recovery and ageing. There is no mechanism argument here: neither compound is proposed to help the other work. That makes this a convenience pairing, which is worth naming because most stacks at least claim more.
A large body of evidence that is also a narrow one.
Epitalon came out of one place: the St Petersburg Institute of Bioregulation and Gerontology, under Vladimir Khavinson. His group has published on it for decades and produced most of what exists.[3]
Volume is not the issue. Concentration is. A finding replicated by twenty labs is a different kind of fact from one reported many times by the same lab, however careful that lab is.
Nobody has published what happens to the compound after it enters a body: how much reaches the blood, how long it lasts, where it goes, how it leaves.[4] For a compound sold and injected for decades, that absence is difficult to explain.
The Russian work in elderly patients is the most striking part of the record, and the hardest to lean on. Those studies were not run to Western standards: patients were not split between groups by chance, nobody was kept unaware of who got what, and there was no dummy-treatment group to compare against. How patients were assigned, whether anyone was blinded, and which statistics were used are not always spelled out in the published reports.[3] Over six to eight years, diet, other medicines and access to a doctor could explain some or all of what they saw.
The gaps are specific, which makes them checkable.
Telomerase is how cancer cells stay alive.
Telomeres are the caps on the ends of chromosomes, and they shorten each time a cell divides. When they run down, the cell stops dividing. Telomerase is the enzyme that rebuilds them, and switching it back on is the headline claim for Epitalon.
Almost every cancer cell switches telomerase back on. It is part of how they keep dividing without limit.[6] So anything that flips the same switch in healthy cells raises an obvious question about what it does to the other kind.
The literature has started to touch this. One analysis looked at cancer cell lines and found Epitalon lengthening telomeres by a second route, one that bypasses telomerase. It flagged that this could in theory help those cells survive.[3] Earlier work from the original group did not explore the question.
This is a theoretical concern raised inside the research literature, not a finding that Epitalon causes cancer. No study has shown that. The point is narrower: the same mechanism being sold as the benefit is the mechanism cancer depends on, and the work needed to separate the two has not been done.
Named for an effect, with no receptor ever found.
DSIP was pulled from the blood of sleeping rabbits in Basel in 1977 and named for what it seemed to do: raise the slow delta waves of deep sleep.[8] Nine amino acids. In those first animal experiments delta activity rose about 35%.[9]
The human work that followed was small. The best of it came from Schneider-Helmert and colleagues, between 1981 and 1987. Placebo-controlled studies in people with chronic insomnia, six to fourteen subjects in each.[10] Some reported longer total sleep, fewer awakenings and better daytime alertness. One 1987 study measuring sleep in a lab found the differences from placebo did not reach clinical significance.
Only one study has ever looked at what DSIP does to sleep in normal men, and it found minor effects.[11] Work on insomnia produced conflicting results across the board, and some studies reported sleep getting worse.[12]
Two things about it are stranger than the mixed record. The body's own DSIP runs opposite to the name. When natural levels rise, slow-wave and REM sleep go down, not up.[8] And in nearly fifty years nobody has isolated the gene that makes it, the protein itself, or any receptor it binds.
A 2006 review in the Journal of Neurochemistry said so in its title. It called DSIP a still unresolved riddle. Its verdict on the sleep claim: extremely poorly documented, and still weak.[12] That assessment is twenty years old and nothing since has overturned it.
So the two halves of this stack share a shape. Epitalon has been injected for forty years with no study of what it does inside a body. DSIP has been named after an effect for fifty years with no receptor found for it. Neither gap proves the compound does nothing. Both mean the mechanism being sold has never been found.
For the pairing specifically: no study has given DSIP alongside Epitalon, in people or animals. Each has its own separate literature, and the combination has none. Epitalon also appears in the three-compound longevity stack alongside GHK-Cu and BPC-157. DSIP turns up in the day and night cognitive stack with Semax and Selank. This is our own searching. It is not a systematic review, and we will correct this page for anyone who can point to a trial.
Nobody collected the side effects, because nobody ran the trials.
Most pages on this site can tell you what percentage of people in a trial had nausea, because a trial counted them against a placebo group. This page cannot.
Neither compound has a registered clinical trial, so no systematic record of side effects exists for either. The Russian work in elderly patients ran for years, but it does not report how patients were assigned, who was kept unaware, or which statistics were used, so safety cannot be read out of it.[3] There is no pharmacokinetic study in any species for Epitalon, so nobody can say how long it stays in the body or where it goes.[4]
A quiet safety record is not the same as a clean one. Both compounds are widely described as well tolerated, and that description rests on the absence of reports rather than on counting. Nobody was counting.
One concern has been named, and it came from the research literature rather than from anyone reporting harm. It is the telomerase question above.
Something in this area does have strong evidence, and it is not either of these.
Chronic insomnia is one of the better-studied problems in medicine. The treatment with the most support behind it involves no compound at all.
It is called CBT-I, short for cognitive behavioural therapy for insomnia. Four separate medical bodies name it as the first thing to try: the American College of Physicians, the American Academy of Sleep Medicine, the British Association for Psychopharmacology and the European Sleep Research Society.[13][14] The ACP calls it a strong recommendation.[13]
It works on the habits and thought patterns that keep insomnia going. How long you lie in bed awake. Daytime napping. The racing thoughts at 2am. The two components carrying most of the effect are stimulus control and sleep restriction.[15] Trials show improvements in how fast people fall asleep, how long they stay awake in the night, and overall sleep quality, and it matches sleeping pills in the short term while beating them over the long run.[13][14]
The honest comparison for this stack is not against doing nothing. It is against a treatment with decades of randomised trials, guideline endorsement across four bodies, and no injection. Access is the real obstacle, since trained therapists are scarce, which is why app-delivered versions are now being trialled in routine care.[16]
None of that rules out a role for these compounds. It does mean anyone reaching for an unstudied injectable for sleep is skipping past the thing that has been studied most.
What people ask about the night stack
Does Epitalon lengthen telomeres in people?
Unknown. In cell cultures it does switch telomerase on. Animal work points the same way. But no controlled trial in healthy people, checked by other labs, has shown that injecting it lengthens telomeres by any amount worth having. The idea is plausible. The human evidence has not confirmed it.
Why do people say all the research comes from one lab?
Because for most of its history it did. Khavinson's institute in St Petersburg produced most of the published work on Epitalon over several decades. Outside labs have replicated little of it, though a 2025 Brunel University study and a 2026 cell study have started to shift that. This concentration is the biggest limit on the whole evidence base.
Could activating telomerase raise cancer risk?
It is a question the research literature has raised and not answered. Telomerase reactivation is a near-universal feature of cancer cells and part of how they divide without limit. One analysis found Epitalon extended telomeres in cancer cell lines through a different route and flagged that this could theoretically help those cells survive. No study has shown that Epitalon causes cancer. The work to rule it out has not been done either.
Does DSIP actually help sleep?
The record is mixed and has stayed mixed. The strongest human work is a set of placebo-controlled studies in chronic insomnia from 1981 to 1987, with six to fourteen people in each. Some found longer sleep and better daytime alertness. A 1987 lab-measured study found the difference from placebo did not reach clinical significance. Only one study has looked at normal sleepers, and it found minor effects. Some studies reported sleep getting worse.
Has a DSIP receptor been found?
No. Nearly fifty years on, three things are still missing: the gene that makes DSIP, the protein itself, and any receptor it binds to. A 2006 review in the Journal of Neurochemistry called it a still unresolved riddle and judged the sleep claim extremely poorly documented. Nothing published since has overturned that.
What actually has evidence for insomnia?
Cognitive behavioural therapy for insomnia, or CBT-I. It is the recommended first treatment across the American College of Physicians, the American Academy of Sleep Medicine, the British Association for Psychopharmacology and the European Sleep Research Society. The ACP grades it a strong recommendation on moderate-quality evidence. It matches sleeping pills in the short term and beats them over the long term. The two components doing most of the work are stimulus control and sleep restriction. The main barrier is finding a trained therapist, which is why app-based versions are being trialled.
What are the side effects of Epitalon and DSIP?
Nobody knows, because nobody counted. Neither compound has a registered clinical trial, so there is no systematic record of adverse events for either. Both are widely described as well tolerated, and that rests on an absence of reports rather than on anyone measuring. The one identified concern is theoretical and comes from the research literature: telomerase activation is a feature of cancer cells, and the work to separate that from the intended effect has not been done.
Is there any reason to run these two together?
Only timing. Both are taken at night and neither is proposed to help the other work. No study has given them together. Most stacks at least claim a mechanism for combining. This one does not. Compare against the other stacks.
Every reference carries how it was read.
The primary Russian literature is largely published in Russian and was not read for this page. Everything below is a secondary account of it, which is itself part of the problem this page describes.
- 02Analysis of the foundational 2003 Khavinson cell culture study, its limitations, and later independent work including a 2025 Brunel University study.
- 03Review of Khavinson peptide bioregulators. Source for the 20 to 40% lifespan claims, the 6 to 8 year elderly cohort follow-ups and their methodological limitations, the 2026 cell study, and the alternative lengthening finding in cancer cell lines.
- 04Evidence quality assessment listing the specific gaps: no registered or completed human trials, no pharmacokinetic or pharmacodynamic studies in any species, no structural biology evidence for the proposed DNA interaction, no lifespan work under Interventions Testing Program standards.
- 05Assessment that no major Western review of ageing biology treats Epitalon telomerase activation as settled.
- 06Telomerase reactivation as a near-universal feature of cancer cells, and the resulting theoretical concern about telomerase activators.
- 08Review of DSIP in the European Journal of Anaesthesiology, 2001. DOI 10.1046/j.1365-2346.2001.00917.x. Source for the 1977 isolation from rabbit brain, the nonapeptide structure, the hypothalamic origin, and the finding that raised endogenous DSIP tracks with suppressed slow-wave and REM sleep.
- 09Original isolation and characterisation of DSIP. DOI 10.1007/bf00581575. Reporting about a 35% increase in EEG delta activity in treated animals against controls.
- 10Schneider-Helmert placebo-controlled studies in chronic insomnia, 1981 to 1987, published in Experientia and European Neurology, 6 to 14 subjects each. PMID 6895513 covers the 1981 acute and delayed effects study, mixed results including a 1987 polysomnographic study where the placebo difference did not reach clinical significance.
- 11Reference work on peptides and sleep, noting that only one study has examined DSIP effects on sleep EEG in normal men and found only minor effects, and that insomnia studies produced conflicting results.
- 12Delta sleep-inducing peptide: a still unresolved riddle. Journal of Neurochemistry, 2006. DOI 10.1111/j.1471-4159.2006.03693.x. Source for the absence of an isolated gene, protein or receptor, for studies failing to confirm slow-wave effects, for reports of impaired sleep, and for the assessment that the sleep-factor hypothesis is extremely poorly documented and weak.
- 13Management of Chronic Insomnia Disorder in Adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine. DOI 10.7326/M15-2175. CBT-I as initial treatment, graded a strong recommendation on moderate-quality evidence, with improvements in remission, sleep onset latency, wake after sleep onset, sleep efficiency and sleep quality.
- 14American Academy of Sleep Medicine clinical practice guideline. DOI 10.5664/jcsm.6470. Plus a British Association for Psychopharmacology consensus statement, both recommending CBT interventions as first-line. Also the finding that CBT-I matches drugs short-term and is superior long-term.
- 15Summary of CBT-I components identifying stimulus control and sleep restriction as carrying most of the effect.
- 16Multicentre randomised trial protocol for app-delivered CBT-I in routine care. PMC12240122. Noting Limited access to in-person CBT-I because of a shortage of trained providers.
- 07Peptide Decoding vendor pricing data, 12 September 2026. Single-compound listings only.